Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: a secondary analysis of the SELECT trial. Presented at: European Congress on Obesity. May 13, 2025. Malaga, Spain. 诺和...
[6] Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes:a meta-analysis [J]. Lancet Diabetes Endocrinol, 2018,6:105-113....
Presented are important clinical trials with cardiovascular (CV) benefit: reduction of major CV events of 12% - 26%, reduction of stroke events of 24% - 39%; and in the PIONEER-6 trial there was a CV and all-cause mortality reduction of 50%, which stimulated the start ...
In order to explore the benefit of GLP-1RAs on cardiovascular events and clarify whether GLP-1RAs should be prescribed to older adults, the authors pooled data from the CVOTs comparing GLP-1RA to placebo stratified by age. Access through your organization Check access to the full text by ...
However, GLP-1 RAs can be combined with (basal) insulin in either free- or fixed-dose preparations. More recently developed agents, in particular semaglutide, are characterized by greater efficacy with respect to lowering plasma glucose as well as body weight. Since 2016, several cardiovascular (...
Like Byetta, Bydureon BCise doesn’t have the same proven cardiovascular benefits seen with other GLP-1 drugs. And it may not result in the same amount of weight loss, either. However, your prescriber may decide that Bydureon BCise is the best option for you. ...
Diabetologia (2025) 68:94–104 https://doi.org/10.1007/s00125-024-06321-2 ARTICLE Racial and ethnic disparities in the uptake of SGLT2is and GLP‑1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic ...
Advancements in glucose-lowering medications have transformed T2D management, with SGLT2 inhibitors and GLP-1 RAs proven to benefit cardiovascular and kidney outcomes.2 These data, however, have not yet confirmed this treatment effect by individual characteristics, including age and sex, with Hanlon a...
The disclosure of proven cardiorenal benefits with certain antidiabetic agents was supposed to herald a new era in the management of type 2 diabetes (T2D), especially for the many patients with T2D who are at high risk for cardiovascular and renal events
cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with semaglutide injection (3.0%) compared to placebo (1.8%). The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline ...